SCHEMBL7938898

SCHEMBL7938898

Cc1cccc2c1-c1c(C)cccc1C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
USP2 O75604 1/20 0.43
HPN P05981 1/20 0.43
ALOX5 P09917 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGS1 P23219 1/20 0.43
PDE4A P27815 1/20 0.43
KDR P35968 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SIRT5 Q9NXA8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21730835 0.87 TDP2 (0.46) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL10692031 0.85 KMT2A (0.57) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL15771707 0.85 CYP1A2 (0.54) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL599052 0.84 MAOA (0.46) TSHRALDH1A1TDP1MEN1KMT2A
SCHEMBL5399227 0.78 TSHR (0.52) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL4652610 0.77 MAOA (0.61) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL30177232 0.77 MAOA (0.61) TSHRALDH1A1CYP3A4TDP1MEN1
SCHEMBL22889028 0.77 METAP1 (0.43) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL2050323 0.77 GRIA1 (0.31) HTR5AGRIA1CACNG8
SCHEMBL21694429 0.77 MAPT (0.45) ALDH1A1TDP1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105654-A Curable resin mixture, curable resin composition, and cured product thereof 日本化药株式会社 2020-12-18 CN disclosed
US-10804474-B2 Organic electroluminescence device and electronic apparatus provided with the same IDEMITSU KOSAN CO., LTD. (JP) 2020-10-13 US disclosed
US-20200111974-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2020-04-09 US disclosed
WO-2020031935-A1 CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT 日本化薬株式会社 2020-02-13 WO disclosed
US-10550209-B2 Catalysts for producing polymers and enhanced properties EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-02-04 US disclosed
US-20180244816-A1 Catalysts for Producing Polymers and Enhanced Properties EXXONMOBIL CHEMICAL PATENTS INC. 2018-08-30 US disclosed
US-9988471-B2 Catalysts for producing polymers with enhanced properties EXXONMOBIL CHEMICAL PATENTS INC (US) 2018-06-05 US disclosed
US-20170174798-A1 Catalysts for Producing Polymers with Enhanced Properties EXXONMOBIL CHEMICAL PATENTS INC. 2017-06-22 US disclosed
WO-2017105635-A1 CATALYSTS FOR PRODUCING POLYMERS WITH ENHANCED PROPERTIES EXXONMOBIL CHEMICAL PATENTS INC. (US) 2017-06-22 WO disclosed
EP-0666267-B1 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM CO (US) 2001-04-18 EP disclosed
US-6114556-A Metallocene compound and its use as catalyst component TARGOR GMBH (DE) 2000-09-05 US disclosed
US-5962359-A Metallocene compound and its use as catalyst component TARGOR GMBH (DE) 1999-10-05 US disclosed
US-5571880-A CATALYSTS FOR POLYMERIZATION OF OLEFINS ESPECIALLY TO OBTAIN SYNDIOTACTIC POLYMERS PHILLIPS PETROLEUM COMPANY (US) 1996-11-05 US disclosed
EP-0723971-A2 Metallocenes and their use as catalyst component HOECHST AKTIENGESELLSCHAFT (DE) 1996-07-31 EP disclosed
EP-0666267-A2 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM COMPANY (US) 1995-08-09 EP disclosed
EP-0531443-A4 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN 1993-04-21 EP disclosed
EP-0531443-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-17 EP disclosed
US-5079260-A Side effect reduction; fluorene derivatives NOVA PHARMACEUTICAL CORPORATION (US) 1992-01-07 US disclosed
WO-1991018596-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN WEITZBERG MOSHE (US) 1991-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550209-B2 Catalysts for producing polymers and enhanced properties PUF60, DBF4, PARN TSHR 4581/4885ALDH1A1 2010/4885CYP3A4 1045/4885
US-20180244816-A1 Catalysts for Producing Polymers and Enhanced Properties PUF60, DBF4, PARN TSHR 4581/4885ALDH1A1 2010/4885CYP3A4 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.